# Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

> **NCT06328036** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Recurrent Glioblastoma, IDH-Wildtype

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Surgical Procedure
- **BIOLOGICAL:** Tiragolumab

## Key facts

- **NCT ID:** NCT06328036
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-30
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other - Protocol moved to Disapproved
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328036, "Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06328036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*